Edition:
United States

Manas Mishra

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

May 24 2018

Medtronic beats estimates on cardio, diabetes gains

Medtronic Plc topped analysts' estimates for profit in the fourth quarter as it kept a tight lid on costs and upped sales of its heart valves and insulin pumps, offsetting the impact of hurricane damage to production in Puerto Rico.

May 23 2018

Merck's cancer drug Keytruda notches another trial success

Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market.

May 21 2018

Nabriva shares tumble as safety worries plague pneumonia drug

Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.

May 16 2018

Evolus investors frown as FDA declines to approve Botox rival

U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.

May 15 2018

Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.

May 10 2018

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.

May 10 2018

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion (1.2 billion pounds) to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.

May 08 2018

Valeant tries to leave the past behind with name change, shares surge

Valeant Pharmaceuticals International Inc said on Tuesday it will change its name to Bausch Health Companies Inc as it seeks to distance itself from a series of scandals and accounting issues under the drug company's previous management.

May 07 2018

Elliott Management makes unsolicited bid for Athenahealth

Elliott Management has proposed an all cash offer of $160 per share for Athenahealth Inc that would value the healthcare software maker at about $6.9 billion including debt, the hedge fund said in a letter Monday.

May 03 2018

Cardinal Health misses profit on Cordis woes, shares fall

Cardinal Health Inc's quarterly profit missed analysts' expectations as inventory and cost issues hurt its Cordis medical device unit, and the U.S. drug distributor said it saw prices of generic drugs fall more than expected.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary